|
1
|
Yu SJ: A concise review of updated
guidelines regarding the management of hepatocellular carcinoma
around the world: 2010–2016. Clin Mol Hepatol. 22:7–17. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Omata M, Cheng AL, Kokudo N, Kudo M, Lee
JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, et al:
Asia-Pacific clinical practice guidelines on the management of
hepatocellular carcinoma: A 2017 update. Hepatol Int. 11:317–370.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
McAllister SS and Weinberg RA: The
tumour-induced systemic environment as a critical regulator of
cancer progression and metastasis. Nat Cell Biol. 16:717–727. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang H and Xu X: Mutation-promoting
molecular networks of uncontrolled inflammation. Tumour Biol.
39:10104283177013102017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ruffini PA, Morandi P, Cabioglu N,
Altundag K and Cristofanilli M: Manipulating the
chemokine-chemokine receptor network to treat cancer. Cancer.
109:2392–2404. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Karin N: Chemokines and cancer: New immune
checkpoints for cancer therapy. Curr Opin Immunol. 51:140–145.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dayer R, Babashah S, Jamshidi S and
Sadeghizadeh M: Upregulation of CXC chemokine receptor 4-CXC
chemokine ligand 12 axis ininvasive breast carcinoma: A potent
biomarker predicting lymph node metastasis. J Cancer Res Ther.
14:345–350. 2018.PubMed/NCBI
|
|
8
|
Mao TL, Fan KF and Liu CL: Targeting the
CXCR4/CXCL12 axis in treating epithelial ovarian cancer. Gene Ther.
24:621–629. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bronger H, Karge A, Dreyer T, Zech D,
Kraeft S, Avril S, Kiechle M and Schmitt M: Induction of cathepsin
B by the CXCR3 chemokines CXCL9 and CXCL10 in human breast cancer
cells. Oncol Lett. 13:4224–4230. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hosono M, Koma YI, Takase N, Urakawa N,
Higashino N, Suemune K, Kodaira H, Nishio M, Shigeoka M, Kakeji Y
and Yokozaki H: CXCL8 derived from tumor-associated macrophages and
esophageal squamous cell carcinomas contributes to tumor
progression by promoting migration and invasion of cancer cells.
Oncotarget. 8:106071–88. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Holmes WE, Lee J, Kuang WJ, Rice GC and
Wood WI: Structure and functional expression of a human
interleukin-8 receptor. Science. 253:1278–1280. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Murphy PM and Tiffany HL: Cloning of
complementary DNA encoding a functional human interleukin-8
receptor. Science. 253:1280–1283. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bi HJ, Wang J, Huang HS and Liu JH:
Influence of IFN on expression of chemokine receptor CXCR1, CXCR2
and their ligand IL-8 in the patients with chronic hepatitis B. Xi
Bao Yu Fen Zi Mian Yi Xue Za Zhi. 28:422–425. 2012.(In Chinese).
PubMed/NCBI
|
|
14
|
Ha H, Debnath B and Neamati N: Role of the
CXCL8-CXCR1/2 axis in cancer and inflammatory diseases.
Theranostics. 7:1543–1588. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu Q, Li A, Tian Y, Wu JD, Liu Y, Li T,
Chen Y, Han X and Wu K: The CXCL8-CXCR1/2 pathways in cancer.
Cytokine Growth Factor Rev. 31:61–71. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Singh S, Sadanandam A, Varney ML, Nannuru
KC and Singh RK: Small interfering RNA-mediated CXCR1 or CXCR2
knock-down inhibits melanoma tumor growth and invasion. Int J
Cancer. 126:328–336. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhu H, Gu Y, Xue Y, Yuan M, Cao X and Liu
Q: CXCR2+ MDSCs promote breast cancer progression by
inducing EMT and activated T cell exhaustion. Oncotarget.
8:114554–114567. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Franz JM, Portela P, Salim PH, Berger M,
Fernando Jobim L, Roesler R, Jobim M and Schwartsmann G: CXCR2
+1208 CT genotype may predict earlier clinical stage at diagnosis
in patients with prostate cancer. Cytokine. 97:193–200. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li A, Varney ML and Singh RK: Expression
of interleukin 8 and its receptors in human colon carcinoma cells
with different metastatic potentials. Clin Cancer Res. 7:3298–3304.
2001.PubMed/NCBI
|
|
20
|
Li Z, Wang Y, Dong S, Ge C, Xiao Y, Li R,
Ma X, Xue Y, Zhang Q, Lv J, et al: Association of CXCR1 and 2
expressions with gastric cancer metastasis in ex vivo and tumor
cell invasion in vitro. Cytokine. 69:6–13. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yung MM, Tang HW, Cai PC, Leung TH, Ngu
SF, Chan KK, Xu D, Yang H, Ngan HY and Chan DW: GRO-α and IL-8
enhance ovarian cancer metastatic potential via the CXCR2-mediated
TAK1/NFκB signaling cascade. Theranostics. 8:1270–1285. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ministry of Health of the People's
Republic of China, . Standard for diagnosis and treatment of
primary hepatocellular carcinoma (2011 edition). Chin J Hepatol.
20:419–426. 2012.(In Chinese).
|
|
23
|
Ren Y, Poon RT, Tsui HT, Chen WH, Li Z,
Lau C, Yu WC and Fan ST: Interleukin-8 serum levels in patients
with hepatocellular carcinoma: Correlations with
clinicopathological features and prognosis. Clin Cancer Res.
9:5996–6001. 2003.PubMed/NCBI
|
|
24
|
Akiba J, Yano H, Ogasawara S, Higaki K and
Kojiro M: Expression and function of interleukin-8 in human
hepatocellular carcinoma. Int J Oncol. 18:257–264. 2001.PubMed/NCBI
|
|
25
|
Wang J, Han Z and Zhou N: Expression of
CXCL8 and its receptors (CXCR1 and CXCR2) in peripheral blood
neutrophils of chronic hepatitis B. Chin J Immunol. 375–379.
383:2015.
|
|
26
|
Xue TC, Chen RX, Ye SL, Sun RX, Chen J and
Tang ZY: Different expressions of chemokine receptors in human
hepatocellular carcinoma cell lines with different metastatic
potentials. Zhonghua Gan Zang Bing Za Zhi. 15:261–265. 2007.(In
Chinese). PubMed/NCBI
|
|
27
|
Huang W, Chen Z, Zhang L, Tian D, Wang D,
Fan D, Wu K and Xia L: Interleukin-8 induces expression of FOXC1 to
promote transactivation of CXCR1 and CCL2 in hepatocellular
carcinoma cell lines and formation of metastases in mice.
Gastroenterology. 149:1053–1067.e14. 2015. View Article : Google Scholar : PubMed/NCBI
|
